Log in

NASDAQ:GNFTGENFIT S A/ADR Stock Price, Forecast & News

$5.42
+0.04 (+0.74 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.34
Now: $5.42
$5.42
50-Day Range
$5.20
MA: $5.57
$6.44
52-Week Range
$5.15
Now: $5.42
$22.48
Volume11,600 shs
Average Volume47,192 shs
Market Capitalization$205.04 million
P/E RatioN/A
Dividend YieldN/A
Beta0.72
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNFT
CUSIPN/A
CIKN/A
Phone33-3-20-16-40-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$45.88 million
Book Value$2.49 per share

Profitability

Miscellaneous

Employees148
Market Cap$205.04 million
Next Earnings Date8/26/2020 (Estimated)
OptionableNot Optionable

Receive GNFT News and Ratings via Email

Sign-up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter.

GENFIT S A/ADR (NASDAQ:GNFT) Frequently Asked Questions

How has GENFIT S A/ADR's stock been impacted by COVID-19 (Coronavirus)?

GENFIT S A/ADR's stock was trading at $14.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GNFT shares have decreased by 61.9% and is now trading at $5.42. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GENFIT S A/ADR?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GENFIT S A/ADR in the last year. There are currently 3 sell ratings, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for GENFIT S A/ADR.

When is GENFIT S A/ADR's next earnings date?

GENFIT S A/ADR is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for GENFIT S A/ADR.

What price target have analysts set for GNFT?

9 brokers have issued 1-year price objectives for GENFIT S A/ADR's shares. Their forecasts range from $7.00 to $174.00. On average, they anticipate GENFIT S A/ADR's stock price to reach $45.20 in the next twelve months. This suggests a possible upside of 733.9% from the stock's current price. View analysts' price targets for GENFIT S A/ADR.

Has GENFIT S A/ADR been receiving favorable news coverage?

Media stories about GNFT stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. GENFIT S A/ADR earned a news impact score of -1.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about GENFIT S A/ADR.

Who are some of GENFIT S A/ADR's key competitors?

What other stocks do shareholders of GENFIT S A/ADR own?

Who are GENFIT S A/ADR's key executives?

GENFIT S A/ADR's management team includes the following people:
  • Mr. Jean-François Mouney, Co-Founder, CEO & Chairman (Age 64)
  • Ms. Nathalie Huitorel, Exec. VP, Chief Financial & Admin. Officer (Age 58)
  • Dr. Dean W. Hum, Chief Operating Officer (Age 57)
  • Prof. Bart Staels, Co-Founder & Pres of the Scientific Advisory Board (Age 56)
  • Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 49)

When did GENFIT S A/ADR IPO?

(GNFT) raised $132 million in an initial public offering (IPO) on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

What is GENFIT S A/ADR's stock symbol?

GENFIT S A/ADR trades on the NASDAQ under the ticker symbol "GNFT."

How do I buy shares of GENFIT S A/ADR?

Shares of GNFT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GENFIT S A/ADR's stock price today?

One share of GNFT stock can currently be purchased for approximately $5.42.

How big of a company is GENFIT S A/ADR?

GENFIT S A/ADR has a market capitalization of $205.04 million and generates $45.88 million in revenue each year. The company earns $-72,960,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. GENFIT S A/ADR employs 148 workers across the globe.

What is GENFIT S A/ADR's official website?

The official website for GENFIT S A/ADR is www.genfit.com.

How can I contact GENFIT S A/ADR?

GENFIT S A/ADR's mailing address is PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company can be reached via phone at 33-3-20-16-40-00 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.